On road to crowded Crohn's disease market, Lilly's Omvoh bests J&J's Stelara in head-to-head study

On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly has notched a trial win over a major rival in a head-to-head study.

When stacked up against Johnson & Johnson’s Stelara, Eli Lilly's Omvoh prompted histologic responses in more patients with moderately to severely active Crohn's disease, regardless of biologic treatment history, by week 52, Lilly reported on Monday.